Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4088044 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.
Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2025-07-24
Completion Date
2027-07
Last Updated
2026-03-02
Healthy Volunteers
Yes
Conditions
Interventions
LY4088044
Administered IV
LY4088044
Administered SC
Placebo
Administered IV
Placebo
Administered SC
Locations (6)
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
ICON
Lenexa, Kansas, United States
ICON Early Phase Services
San Antonio, Texas, United States
ICON
Salt Lake City, Utah, United States
New Zealand Clinical Research Christchurch
Christchurch, New Zealand
Lilly Centre for Clinical Pharmacology
Singapore, Singapore